PET scan to tell tumor growth from treatment effects in brain cancer
Part of Cancer clinical trials.
This trial tests whether a special PET scan can tell the difference between actual tumor growth and treatment-related changes in people with aggressive brain cancer (high-grade glioma). If you have had radiation and an MRI shows a growing lesion, this study may help clarify the cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older
- You have a confirmed high-grade glioma (WHO grade 3 or 4) that has been treated with radiation
- Your latest MRI shows a new or growing spot within the radiation area
- Your tumor is IDH wild-type (a specific genetic type)
- You have not had prior treatment with bevacizumab or similar anti-angiogenic drugs
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study uses a special PET scan plus MRI to help doctors tell apart tumor changes in children with aggressive gliomas. It may help find whether treatment is working or if the tumor is progressing, while also mapping tumor activity in the brain.
This early-phase study uses special PET/MRI scans to look at how a newly diagnosed high-grade glioma is changing under standard treatment. The goal is to see whether these scans can better assess the disease, which may help guide future care.
This trial tests whether using a special PET scan (a type of imaging that shows tumor activity) during brain tumor surgery helps doctors remove more of the tumor safely. You would have a high-grade glioma (an aggressive brain cancer) and be scheduled for surgery.
This trial uses a special type of PET scan (FET-PET) to help doctors distinguish between pseudoprogression (a temporary reaction to treatment that can look like tumor growth on MRI) and actual tumor recurrence in people with glioblastoma. The goal is to improve management decisions and avoid unnecessary treatments.
This study tests a special imaging agent called fluoroethyltyrosine (FET) to see if it can better detect brain tumors on PET scans. It may help doctors decide if a tumor has come back after treatment or better guide initial biopsy or surgery.
This study looks at how well a specific PET scan (using a tracer called [18F]FET) can help doctors diagnose brain tumors, check how well treatment is working, or spot tumors that come back. Researchers will analyze images you may have already had or will have as part of your regular care.
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.